Mortality Trend in Patients With Heart Failure and Psychoactive Substance Abuse in the United States—Pre‐ and Post‐COVID‐19 Pandemic Perspective (1999−2023)
Clinical Cardiology · 2026
DOI: 10.1002/clc.70425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, 2026. Verfasst von Emad Uddin Sajid und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Heart Failure, Substance-Related Disorders, COVID-19, Psychotropic Drugs. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
This study evaluates national trends in heart failure (HF) and psychoactive substance abuse‐related mortality among adults aged 25 years and older in the United States (US) from 1999 to 2023, stratified by sex, age, race/ethnicity, geographic regions, and the COVID‐19 pandemic period.
Methods
Data from 1999 to 2023 were extracted from the CDC WONDER database. Age‐adjusted mortality rates (AAMR) and annual percentage changes (APC) were calculated using Joinpoint regression. ICD‐10 codes I50, I50.1, I50.9 (Heart Failure), and F10‐19 (Psychoactive Substance Use) were used to identify the conditions.
Results
A total of 771 739 deaths were recorded from 1999 to 2023 among individuals aged 25 and older. Most deaths occurred in medical facilities (39.24%), followed by decedents' homes (34.14%), long‐term care facilities (16.30%), hospice (6.65%), and other settings (3.67%). The AAMR increased markedly from 1.68 in 1999 to 20.7 in 2023 (AAPC of 12.09, 95% confidence interval [CI]: 10.97−14.26). A substantial increase was observed from 1999 to 2005 (APC: 38.5%, 95% CI: 29.1–55.8), followed by a slower increase until 2020 (APC: 5.68%, 95% CI: 5.02–14.8). Men showed consistently higher AAMRs than females (18.8 vs. 8.65). By age group, mortality was highest among individuals aged 65 years and older.
Conclusion
Using CDC WONDER data (1999–2023), we found a sharp rise in HF mortality linked to psychoactive substance abuse, from 1.68 to 20.7 per 100 000. Mortality burden was highest among males, older adults, non‐Hispanic White individuals, and rural populations, highlighting widening demographic and geographic disparities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Dow Medical College, DUHS, Karachi, Pakistan.
- Dow University of Health Sciences, Karachi, Pakistan.
- Dow Institute of Cardiology, DUHS, Karachi, Pakistan.
- Voice of Doctors Research School, Dhaka, Bangladesh.
- Department of Public Health, Atish Dipankar University of Science and Technology, Dhaka, Bangladesh.
ORCID-Profile: Emad Uddin Sajid, Ayesha Irfan, Muhammad Kashan, Syed Rayyan Ahmed, Muhammad Hasnain Azeem, Tooba Ali, Mabel Waqar, Muneeba Khan, Erum Shahzadi Malik, Md Ariful Haque
Zitieren
APA
Sajid, E. U., Irfan, A., Kashan, M., Ahmed, S. R., Azeem, M. H., Ali, T., Waqar, M., Khan, M., Malik, E. S., & Haque, M. A. (2026). Mortality Trend in Patients With Heart Failure and Psychoactive Substance Abuse in the United States—Pre‐ and Post‐COVID‐19 Pandemic Perspective (1999−2023). Clinical Cardiology. https://doi.org/10.1002/clc.70425
Vancouver
Sajid EU, Irfan A, Kashan M, Ahmed SR, Azeem MH, Ali T, et al. Mortality Trend in Patients With Heart Failure and Psychoactive Substance Abuse in the United States—Pre‐ and Post‐COVID‐19 Pandemic Perspective (1999−2023). Clinical Cardiology. 2026. doi:10.1002/clc.70425
BibTeX
@article{Sajid2026,
author = {Sajid, Emad Uddin and Irfan, Ayesha and Kashan, Muhammad and Ahmed, Syed Rayyan and Azeem, Muhammad Hasnain and Ali, Tooba and Waqar, Mabel and Khan, Muneeba and Malik, Erum Shahzadi and Haque, Md Ariful},
title = {Mortality Trend in Patients With Heart Failure and Psychoactive Substance Abuse in the United States—Pre‐ and Post‐COVID‐19 Pandemic Perspective (1999−2023)},
journal = {Clinical Cardiology},
year = {2026},
doi = {10.1002/clc.70425}
}
EUVIMED